BERINERT 1500 KIT

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

C1 ESTERASE INHIBITOR (HUMAN)

Disponibbli minn:

CSL BEHRING CANADA INC

Kodiċi ATC:

B06AC01

INN (Isem Internazzjonali):

C1-INHIBITOR, PLASMA DERIVED

Dożaġġ:

1500UNIT

Għamla farmaċewtika:

KIT

Kompożizzjoni:

C1 ESTERASE INHIBITOR (HUMAN) 1500UNIT

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

3ML

Tip ta 'preskrizzjoni:

Schedule D

Żona terapewtika:

COMPLEMENT INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0152746002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2014-12-23

Karatteristiċi tal-prodott

Page 1 of 45
PRODUCT MONOGRAPH
BERINERT
® 500 / BERINERT
® 1500
C1 ESTERASE INHIBITOR, HUMAN
Powder and Diluent for Solution for Injection
For Intravenous Administration
500 IU/vial, reconstituted with 10 mL of diluent
1500 IU/vial, reconstituted with 3 mL of diluent
CSL Behring Canada, Inc.
55 Metcalfe Street, Suite 1460
Ottawa, Ontario
K1P 6L5
Date of Initial Approval: May 31, 2010
Date of Revision: February 14, 2020
Submission Control No: 235563
Page 2 of 45
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
...............................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 15
STORAGE AND STABILITY
.........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 18
PART II: SCIENTIFIC INFORMATION
..............................................................................
19
PHARMACEUTICAL INFORMATION
.........................................................................
19
CLINICAL TRIAL